Shareholder alert: robbins llp informs investors of class action against y-mabs therapeutics, inc. (ymab)

San diego--( business wire )--the class: robbins llp informs investors that a shareholder filed a class action on behalf of all investors who purchased shares of y-mabs therapeutics, inc. (nasdaq: ymab) common stock between october 6, 2020 and october 28, 2022, for violations of the securities exchange act of 1934. y-mabs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages. the company's lead product candidate is omburtamab, a murine monoclonal antibody that targets b7-h3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types. according to y-mabs, "131i-omburtamab, which is omburtamab radiolabeled with iodine-131, is currently being studied in several clinical trials including pivotal stage development study 101 and study 03-133 for the treatment of pediatric patients who have cns/lm from nb.”
YMAB Ratings Summary
YMAB Quant Ranking